Arcturus Therapeutics Announces $10.9 Million Registered Direct Offering of Common Stock
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/27/2026
- Nasdaq leads Wall St higher as Nvidia eases AI growth concerns
- Nvidia forecasts 70% sales growth next year, signals AI spending boom has years left to run
- Oil prices rise as investors weigh lack of progress in Middle East negotiations
- Could SpaceX's orbital compute avoid the political headwinds facing data centers?
- Could Meta's teen settlement be less painful than feared? Citi weighs in
- Nutanix (NTNX) Tops Q4 EPS by 11c, Beats in Revenue; Offers Q1 Revenue Guidance
- Boston Scientific discloses cybersecurity incident causing global disruption
- Crude Inventory Rose 0.1 Million Barrels Last Week - EIA
- Revolution Medicines prices RASONQUE at $39,800 per month
- Wall Street stocks end tad lower after hot inflation data ahead of Nvidia earnings
Arcturus Therapeutics (ARCT) Announces $2.3 Million Additional Registered Direct Offering of Common Stock
August 2, 2019 2:03 PM EDTArcturus Therapeutics (Nasdaq: ARCT) a leading RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases, today announced that it has entered into a definitive agreement with an institutional investor for the purchase and sale in a registered direct offering of 200,000 shares of the Companys common stock, at a purchase price of $11.50 per share, for aggregate gross proceeds of $2.3 million. The offering is expected to close on or about August 5, 2019, subject to the satisfaction of customary... More
